# Jia Zhong

## List of Publications by Citations



| 24 | 184 | 7 | 12 |
|---|---|---|---|
| papers | citations | h-index | g-index |
| 27 | 281 | 3.7 | 2.35 |
| ext. papers | ext. citations | avg, IF | L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 24 | Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). *Journal of Thoracic Oncology*, **2017**, 12, 1766-1778 | 8.9 | 35 |
| 23 | The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. *Clinical Cancer Research*, **2020**, 26, 892-901 | 12.9 | 34 |
| 22 | ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. *Thoracic Cancer*, **2019**, 10, 2088-2095 | 3.2 | 14 |
| 21 | Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2017**, 29, 553-560 | 3.8 | 10 |
| 20 | Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. *Thoracic Cancer*, **2014**, 5, 509-16 | 3.2 | 9 |
| 19 | A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. *BMC Cancer*, **2020**, 20, 666 | 4.8 | 8 |
| 18 | Survival comparison of right and left side non-small cell lung cancer in stage I-IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis. *Thoracic Cancer*, **2019**, 10, 459-471 | 3.2 | 8 |
| 17 | Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 1166-1173 | 3.2 | 7 |
| 16 | Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. *Annals of Translational Medicine*, **2021**, 9, 33 | 3.2 | 7 |
| 15 | Optimal first-line treatment for advanced thymic carcinoma. *Thoracic Cancer*, **2019**, 10, 2081-2087 | 3.2 | 6 |
| 14 | Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. *BMC Cancer*, **2020**, 20, 793 | 4.8 | 6 |
| 13 | Analysis of MET kinase domain rearrangement in NSCLC. *Lung Cancer*, **2020**, 145, 140-143 | 5.9 | 5 |
| 12 | Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. *Frontiers in Oncology*, **2020**, 10, 626 | 5.3 | 5 |
| 11 | Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. *Thoracic Cancer*, **2019**, 10, 1788-1797 | 3.2 | 5 |
| 10 | Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. *Frontiers in Molecular Biosciences*, **2021**, 8, 639892 | 5.6 | 5 |
| 9 | Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. *Thoracic Cancer*, **2019**, 10, 1193-1202 | 3.2 | 4 |
| 8 | Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. *Thoracic Cancer*, **2018**, 9, 291-297 | 3.2 | 4 |

# List of Publications

| | | | |
|---|---|---|---|
| 7 | Synchronous breast cancer and breast lymphoma: two case reports and literature review. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2014**, 26, 355-9 | 3.8 | 3 |
| 6 | Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. *Frontiers in Oncology*, **2020**, 10, 1137 | 5.3 | 3 |
| 5 | Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. *Thoracic Cancer*, **2020**, 11, 1149-1159 | 3.2 | 2 |
| 4 | A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer.. *Journal of Clinical Oncology*, **2021**, 39, e21053-e21053 | 2.2 | 1 |
| 3 | Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. *Cancer Cell International*, **2020**, 20, 590 | 6.4 | |
| 2 | cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, e14555-e14555 | 2.2 | |
| 1 | EML4-ALK rearrangement detection in malignant pleural effusions from patients with advanced non-small cell lung cancer: Feasibility and predictive value.. *Journal of Clinical Oncology*, **2015**, 33, e19094-e19094 | 2.2 | |